Cargando…
Expression of Tumor‐rejection Antigens in Gynecologic Cancers
We recently reported the four tumor‐rejection antigens (SART1(259) SART2, SART3, and ART4) that possess tumor epitopes capable of inducing HLA‐A2402‐restricted cytotoxic T lymphocytes (CTLs) in cancer patients. This study investigated the expression of these tumor antigens in gynecologic cancers, in...
Autores principales: | Tanaka, Shoko, Tsuda, Naotake, Kawano, Kouichirou, Sakamoto, Masaru, Nishida, Takashi, Hashimoto, Takashi, Shichijo, Shigeki, Kamura, Toshiharu, Itoh, Kyogo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926290/ https://www.ncbi.nlm.nih.gov/pubmed/11092984 http://dx.doi.org/10.1111/j.1349-7006.2000.tb00902.x |
Ejemplares similares
-
Expression of the SART‐1 Antigens in Uterine Cancers
por: Matsumoto, Hajime, et al.
Publicado: (1998) -
Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides
por: Fukui, Akimasa, et al.
Publicado: (2012) -
Sequence Analysis of Genes Encoding Rodent Homologues of the Human Tumor‐rejection Antigen SART‐1
por: Gotoh, Masashi, et al.
Publicado: (1998) -
Prevention of lymphocele development in gynecologic cancers by the electrothermal bipolar vessel sealing device
por: Tsuda, Naotake, et al.
Publicado: (2014) -
Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy
por: Kawano, Kouichiro, et al.
Publicado: (2015)